Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development
Status: | Completed |
---|---|
Conditions: | Prostate Cancer, Cancer, Cancer, Cancer, Bladder Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 10/13/2017 |
Start Date: | August 2013 |
End Date: | April 2016 |
Development of a Novel Technique for PET/MRI Tracer Kinetic Analysis for Urologic Pelvic Malignancy
The purpose of this study is to develop a novel technique for integrated PET/MRI tracer
kinetic analysis for urologic malignancy.
kinetic analysis for urologic malignancy.
Patients scheduled to undergo gadolinium-enhanced MRI for urologic malignancy will be
recruited to undergo PET/MRI employing simultaneous dynamic acquisition of PET and
gadolinium-chelate data sets. For initial technical development within this pilot study,
analysis will be performed attempting to compute tracer delivery using inputs from an
integrated MRI-perfusion analysis. Flow and permeability will be obtained from the MR
perfusion analysis, which can be used to compute the inflow rate constant K1. K1, reflecting
the transfer of contrast, will then be used to compute the metabolic uptake of FDG by the
organ as well as of any visible tumors. A determination will be made whether this metabolic
uptake is successfully computed for each case. If not, then acquisition and post-processing
modifications will be made for subsequent cases.
recruited to undergo PET/MRI employing simultaneous dynamic acquisition of PET and
gadolinium-chelate data sets. For initial technical development within this pilot study,
analysis will be performed attempting to compute tracer delivery using inputs from an
integrated MRI-perfusion analysis. Flow and permeability will be obtained from the MR
perfusion analysis, which can be used to compute the inflow rate constant K1. K1, reflecting
the transfer of contrast, will then be used to compute the metabolic uptake of FDG by the
organ as well as of any visible tumors. A determination will be made whether this metabolic
uptake is successfully computed for each case. If not, then acquisition and post-processing
modifications will be made for subsequent cases.
Inclusion Criteria:
The study population will consist of patients with known urologic cancer who are scheduled
to undergo MRI with gadolinium for their routine care. Patients will be referred by the
Urology or Medical Oncology Departments for participation in the study. Subjects will be
selected on the basis of their willingness and ability to participate and on their
likelihood of completing the study. Patients agreeing to participate will be presented with
a flyer which will inform subject about the available research study and study contact
information. participation is entirely voluntary, and a subject may withdraw from the study
at any time. Normal volunteers will be recruited accessing the existing database of normal
volunteers maintained in Radiology Research department.
Exclusion Criteria:
Normal MRI exclusion criteria will apply, including those on the following list. A standard
MRI safety form will be used to identify potential conditions warranting exclusion.
- Electrical implants such as cardiac pacemakers or perfusion pumps
- Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial
heart, valves with steel parts, metal fragments, shrapnel, bullets, tattoos near the
eye, or steel implants
- Ferromagnetic objects such as jewelry or metal clips in clothing
- Claustrophobia
- History of seizures
We found this trial at
1
site
New York, New York 10016
Principal Investigator: Andrew B Rosenkrantz, MD MPA
Phone: 212-263-2710
Click here to add this to my saved trials